0QF:F:F-Moderna Inc (EUR)

COMMON STOCK | Biotechnology |

Last Closing

USD 61

Change

-2.00 (-3.17)%

Market Cap

USD 24.20B

Volume

1.10K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-19 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
RGO:F Regeneron Pharmaceuticals Inc

N/A

USD 84.33B
CSJ:F CSL Limited

N/A

USD 83.49B
CSJA:F CSL LTD SPON.ADR 2

N/A

USD 82.40B
UNC0:F UCB S.A. UNSP.ADR 1/2

N/A

USD 34.23B
1AEA:F argenx SE

N/A

USD 33.08B
1AE:F Argen-X

N/A

USD 32.90B
DUL:F Alnylam Pharmaceuticals Inc

N/A

USD 32.23B
22UA:F BioNTech SE

N/A

USD 24.86B
49BA:F BeiGene Ltd

N/A

USD 22.99B
49B:F BeiGene Ltd.

N/A

USD 21.35B

ETFs Containing 0QF:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -31.77% 34% F 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -31.77% 34% F 16% F
Trailing 12 Months  
Capital Gain -42.18% 33% F 15% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -42.18% 33% F 15% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -3.28% 57% F 36% F
Dividend Return -3.28% 56% F 32% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 56.62% 23% F 18% F
Risk Adjusted Return -5.80% 61% D- 37% F
Market Capitalization 24.20B 98% N/A 92% A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector